The first and only treatment for early-onset, severe or serious 5-FU toxicity 1, 2, 19

Vistogard® (uridine triacetate) oral granules—a documented safety profile 1, 2, 19

Treat with confidence

Adverse reactions occurring in >2% of patients (N=135)
Adverse Reactions Number of Patients Percent of Patients
Vomiting 13 10%
Nausea 7 5%
Diarrhea 4 3%
  • No contraindications, warnings, precautions, or cytochrome P450 drug–drug interactions4
  • May be taken without regard to meals4
  • Pharmacokinetics were not significantly affected by gender or age (in patients aged 20 to 83 years)4
  • Geriatric patients: Of the 135 patients in clinical studies with Vistogard®, 30% were ≥65, including 11% ≥75
  • One patient receiving Vistogard® had Grade 3 nausea and vomiting4
  • Vistogard® was discontinued for adverse reactions in 2 (1.4%) patients4


VISTOGARD is indicated for the emergency treatment of adult and pediatric patients:

  • following a fluorouracil or capecitabine overdose regardless of the presence of symptoms, or
  • who exhibit early-onset, severe or life-threatening toxicity affecting the cardiac or central nervous system, and/or early-onset, unusually severe adverse reactions (e.g., gastrointestinal toxicity and/or neutropenia) within 96 hours following the end of fluorouracil or capecitabine administration.

Limitations of use

  • VISTOGARD is not recommended for the non–emergent treatment of adverse reactions associated with fluorouracil or capecitabine because it may diminish the efficacy of these drugs.
  • The safety and efficacy of VISTOGARD initiated more than 96 hours following the end of fluorouracil or capecitabine administration have not been established.